Pillstats
Rx only · Injection, Powder, Lyophilized, For Solution · Intravenous

Fosaprepitant

Brands: Navitrux · Fosaprepitant Dimeglumine

10 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US14 NDCs
10 active makers
UKComing
soon
CAComing
soon
AUComing
soon
EUComing
soon
ATC—
RxCUI (US)1731071
US makers10 labelers
Packages13
DEA / ScheduleNone

Medicaid dispensing volumeSDUD · per quarter

Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.

4.4K8.9K13K18K2025 Q12025 Q22025 Q32025 Q42026 Q1
11K
Rx · 2026 Q1
11K
Units dispensed
-17%
Rx vs. year ago
5
Quarters · since 2025 Q1

Who makes it10 active · 0 exited

US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.

LabelerTypePackagesStatus
Dr.Reddy's laboratories Limitedunknown3SUPPLYING
Novadoz Pharmaceuticals LLCunknown2SUPPLYING
Actavis Pharma, Inc.unknown1SUPPLYING
NorthStar Rx LLCunknown1SUPPLYING
Fresenius Kabi USA, LLCunknown1SUPPLYING
Avyxa Pharma, LLCunknown1SUPPLYING
BluePoint Laboratoriesunknown1SUPPLYING
Mylan Institutional LLCunknown1SUPPLYING
BE Pharmaceuticals Inc.unknown1SUPPLYING
Bryant Ranch Prepackrepackager1SUPPLYING

Regulatory & supply eventsFDA · US

Shortages, recalls, and registration changes attached to this drug concept.

  • Apr 8, 2026
    RESOLVEDShortage resolved: Fosaprepitant Dimeglumine Injection (Fresenius Kabi USA, LLC)

    Fosaprepitant Dimeglumine Injection — reported in shortage by Fresenius Kabi USA, LLC. Therapeutic category: Gastroenterology.

  • Apr 8, 2026
    SHORTAGEDrug shortage: Fosaprepitant Dimeglumine Injection (Fresenius Kabi USA, LLC)

    Fosaprepitant Dimeglumine Injection — reported in shortage by Fresenius Kabi USA, LLC. Therapeutic category: Gastroenterology.

  • Jan 10, 2024
    RECALLRecall (Class II): Fosaprepitant for Injection 150 mg per vial, Sterile lyophilized powder for Intravenous use only after reconstitution a…

    Lack of Sterility Assurance: Aseptic process simulation failure. — Recalling firm: BE PHARMACEUTICALS AG — Nationwide in the USA

  • Jul 13, 2020
    RECALLRecall (Class III): Fosaprepitant for Injection, 150 mg / vial in a 10 mL Single-Dose vial, Rx only, Fresenius Kabi, Lake Zurich, IL 60047;…

    Labeling Error: Label Error on Declared Strength: Carton label and product insert incorrectly states the quantity of the excipient edetate disodium (EDTA) as 5.4 mg / vial, rather than the actual amount of 18.8 mg / vial. — Recalling firm: Fresenius Kabi USA, LLC — Nationwide within the United States